Valuation: Viking Therapeutics, Inc.

Market Cap 3.44B 2.98B 2.82B 2.56B 4.8B 330B 4.83B 33.67B 13.01B 168B 12.94B 12.65B 534B P/E 2026 *
-6.4x
P/E 2027 * -6.95x
Enterprise Value 3B 2.6B 2.46B 2.23B 4.19B 288B 4.21B 29.38B 11.35B 146B 11.29B 11.04B 466B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.91%
Yield 2026 *
-
Yield 2027 * -
1 day-1.44%
1 week-9.72%
Current month-9.95%
1 month-11.06%
3 months-0.44%
6 months-18.02%
Current year-16.09%
1 week 28.8
Extreme 28.8
33.05
1 month 28.8
Extreme 28.8
36.26
Current year 25.77
Extreme 25.77
42.79
1 year 23.06
Extreme 23.06
43.15
3 years 8.28
Extreme 8.28
99.41
5 years 2.02
Extreme 2.02
99.41
10 years 0.88
Extreme 0.88
99.41
Manager TitleAgeSince
Chief Executive Officer 60 24/09/2012
Director of Finance/CFO 55 04/01/2021
Chief Tech/Sci/R&D Officer 57 11/06/2026
Director TitleAgeSince
Chairman 68 01/05/2015
Chairman 60 24/09/2012
Director/Board Member 53 01/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Free

Director

47,133 0.0404%
29/07/26 Sell

Chief Operating Officer

-18,217 0.0157%
29/07/26 Sell

Founder

-148,517 0.1279%
Change 5-day change 1-year change 3-year change Capi.($)
-1.44%-9.72%+24.61%+99.86% 3.49B
+0.66%+1.83%+47.32%+97.63% 69.18B
-1.19%-1.92%+34.57%+73.08% 62B
+2.22%-4.83%-15.32%+360.65% 26.19B
+0.72%+5.79%+28.12%+15.25% 25.75B
-0.89%-2.34%-3.46%-15.24% 24.29B
+2.84%+3.61%+24.60%-17.13% 19.84B
0.00%-10.41%+171.96%+298.75% 15.65B
-0.21%-2.66%+45.07%+160.34% 14.1B
+0.74%-2.19%-9.29%+459.04% 14.09B
Average +0.34%-2.95%+34.82%+153.22% 27.46B
Weighted average by Cap. +0.30%-1.36%+34.33%+124.43%

Financials

2026 *2027 *
Net sales - -
Net income -541M -469M -443M -402M -754M -51.92B -759M -5.29B -2.04B -26.33B -2.03B -1.99B -83.94B -539M -467M -442M -401M -752M -51.73B -756M -5.27B -2.04B -26.24B -2.03B -1.98B -83.64B
Net Debt -439M -381M -360M -327M -612M -42.14B -616M -4.3B -1.66B -21.37B -1.65B -1.61B -68.13B -520M -450M -426M -386M -724M -49.86B -729M -5.08B -1.96B -25.29B -1.95B -1.91B -80.61B
Logo Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Employees
65
Date Price Change Volume
16/09/26 $29.52 -1.44% 3,005,511
15/09/26 $29.95 -5.01% 2,807,988
14/09/26 $31.53 -1.41% 1,849,102
11/09/26 $31.98 -0.47% 2,207,193
10/09/26 $32.13 -1.74% 1,715,157
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
29.52USD
Average target price
92.39USD
Spread / Average Target
+212.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VKTX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!